232 related articles for article (PubMed ID: 32856614)
21. New cancer biomarkers deriving from NCI early detection research.
Verma M; Srivastava S
Recent Results Cancer Res; 2003; 163():72-84; discussion 264-6. PubMed ID: 12903844
[TBL] [Abstract][Full Text] [Related]
22. Biomarkers in Lung Cancer.
Sears CR; Mazzone PJ
Clin Chest Med; 2020 Mar; 41(1):115-127. PubMed ID: 32008624
[TBL] [Abstract][Full Text] [Related]
23. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications.
Ocak S; Sos ML; Thomas RK; Massion PP
Eur Respir J; 2009 Aug; 34(2):489-506. PubMed ID: 19648524
[TBL] [Abstract][Full Text] [Related]
24. Lung cancer epigenetics and genetics.
Risch A; Plass C
Int J Cancer; 2008 Jul; 123(1):1-7. PubMed ID: 18425819
[TBL] [Abstract][Full Text] [Related]
25. Cellular and molecular immunology of lung cancer: therapeutic implications.
Nguyen AH; Berim IG; Agrawal DK
Expert Rev Clin Immunol; 2014 Dec; 10(12):1711-30. PubMed ID: 25351434
[TBL] [Abstract][Full Text] [Related]
26. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
Bhalla S; Doroshow DB; Hirsch FR
Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
[TBL] [Abstract][Full Text] [Related]
27. Biomarkers for personalized oncology: recent advances and future challenges.
Kalia M
Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
[TBL] [Abstract][Full Text] [Related]
28. Cancer interception.
Blackburn EH
Cancer Prev Res (Phila); 2011 Jun; 4(6):787-92. PubMed ID: 21636545
[TBL] [Abstract][Full Text] [Related]
29. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
30. Immune Stroma in Lung Cancer and Idiopathic Pulmonary Fibrosis: A Common Biologic Landscape?
Lettieri S; Oggionni T; Lancia A; Bortolotto C; Stella GM
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809111
[TBL] [Abstract][Full Text] [Related]
31. Immune Therapy.
Lievense L; Aerts J; Hegmans J
Adv Exp Med Biol; 2016; 893():59-90. PubMed ID: 26667339
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers for lung cancer: clinical uses.
Greenberg AK; Lee MS
Curr Opin Pulm Med; 2007 Jul; 13(4):249-55. PubMed ID: 17534168
[TBL] [Abstract][Full Text] [Related]
33. Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Anagnostou V; Forde PM; White JR; Niknafs N; Hruban C; Naidoo J; Marrone K; Sivakumar IKA; Bruhm DC; Rosner S; Phallen J; Leal A; Adleff V; Smith KN; Cottrell TR; Rhymee L; Palsgrove DN; Hann CL; Levy B; Feliciano J; Georgiades C; Verde F; Illei P; Li QK; Gabrielson E; Brock MV; Isbell JM; Sauter JL; Taube J; Scharpf RB; Karchin R; Pardoll DM; Chaft JE; Hellmann MD; Brahmer JR; Velculescu VE
Cancer Res; 2019 Mar; 79(6):1214-1225. PubMed ID: 30541742
[TBL] [Abstract][Full Text] [Related]
34. Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms.
Monteiro ID; Califano R; Mountzios G; de Mello RA
Future Oncol; 2016 Feb; 12(4):551-64. PubMed ID: 26776915
[TBL] [Abstract][Full Text] [Related]
35. Potential biomarkers for predicting immune response and outcomes in lung cancer patients undergoing thermal ablation.
Sang J; Ye X
Front Immunol; 2023; 14():1268331. PubMed ID: 38022658
[TBL] [Abstract][Full Text] [Related]
36. IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.
Caetano MS; Zhang H; Cumpian AM; Gong L; Unver N; Ostrin EJ; Daliri S; Chang SH; Ochoa CE; Hanash S; Behrens C; Wistuba II; Sternberg C; Kadara H; Ferreira CG; Watowich SS; Moghaddam SJ
Cancer Res; 2016 Jun; 76(11):3189-99. PubMed ID: 27197187
[TBL] [Abstract][Full Text] [Related]
37. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
38. Role of biomarkers for early detection of lung cancer and chemoprevention.
Hirsch FR; Merrick DT; Franklin WA
Eur Respir J; 2002 Jun; 19(6):1151-8. PubMed ID: 12108871
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
